KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Total Non-Current Liabilities (2018 - 2024)

Aurinia Pharmaceuticals' Total Non-Current Liabilities history spans 6 years, with the latest figure at $162.1 million for Q4 2024.

  • For Q4 2024, Total Non-Current Liabilities rose 1.8% year-over-year to $162.1 million; the TTM value through Dec 2024 reached $162.1 million, up 1.8%, while the annual FY2024 figure was $162.1 million, 1.8% up from the prior year.
  • Total Non-Current Liabilities reached $162.1 million in Q4 2024 per AUPH's latest filing, up from $150.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $162.1 million in Q4 2024 to a low of $29.0 million in Q1 2021.
  • Average Total Non-Current Liabilities over 4 years is $91.2 million, with a median of $51.1 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: surged 251.47% in 2023, then fell 1.49% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $48.3 million in 2021, then rose by 10.14% to $53.2 million in 2022, then soared by 199.1% to $159.2 million in 2023, then increased by 1.8% to $162.1 million in 2024.
  • Per Business Quant, the three most recent readings for AUPH's Total Non-Current Liabilities are $162.1 million (Q4 2024), $150.5 million (Q3 2024), and $148.0 million (Q2 2024).